Prevalence and risk factors for unrecognized obstructive lung disease among urban drug users

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 89-95

  Drummond, M Bradley ^a   Kirk, Gregory D ^a,b   Astemborski, Jacquie ^b   McCormack, Meredith C ^a   Marshall, Mariah M ^b   Mehta, Shruti H ^b   Wise, Robert A ^a   Merlo, Christian A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Asthma; COPD; Human immunodeficiency virus infection; Obstructive lung disease; Spirometry

Indexed keywords

ADULT; ANTIVIRAL THERAPY; ARTICLE; ASYMPTOMATIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CROSS-SECTIONAL STUDY; DELAYED DIAGNOSIS; DISEASE SEVERITY; DRUG ABUSE; DYSPNEA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK FACTOR; SPIROMETRY; URBAN POPULATION;

ADULT; BALTIMORE; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; DRUG USERS; FEMALE; HUMANS; LUNG; LUNG DISEASES, OBSTRUCTIVE; MALE; MIDDLE AGED; PREVALENCE; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SPIROMETRY; SUBSTANCE ABUSE, INTRAVENOUS; URBAN POPULATION;

EID: 79251495084     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S15968     Document Type: Article

References (47)

1. Gomez FP, Rodriguez-Roisin R. Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2002;8(2):81-86.
2. McHugh MK, Symanski E, Pompeii LA, Delclos GL. Prevalence of asthma among adult females and males in the United States: results from the National Health and Nutrition Examination Survey (NHANES), 2001-2004. J Asthma. 2009;46(8):759-766.
3. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma-United States, 1980-1999. MMWR Surveill Summ. 2002;51(1):1-13.
4. Mannino DM. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest. 2002;121 (Suppl 5): 121S-126S.
5. Banerjee DK, Lee GS, Malik SK, Daly S. Underdiagnosis of asthma in the elderly. Br J Dis Chest. 1987;81(1):23-29.
6. Renwick DS, Connolly MJ. Prevalence and treatment of chronic airways obstruction in adults over the age of 45. Thorax. 1996;51(2): 164-168.
7. Dales RE, Aaron SD, Vandemheen KL, Mehdizadeh A, Clinch J. The prevalence of airflow obstruction in rural primary care. Respir Med. 2006;100(4):754-759.
8. Snyder LD, Eisner MD. Obstructive lung disease among the urban homeless. Chest. 2004;125(5):1719-1725.
9. Zaas D, Wise R, Wiener C. Airway obstruction is common but unsuspected in patients admitted to a general medicine service. Chest. 2004; 125(1):106-111.
10. Damarla M, Celli BR, Mullerova HX, Pinto-Plata VM. Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respir Care. 2006;51(10):1120-1124.
11. Schoener EP, Hopper JA, Pierre JD. Injection drug use in North America. Infect Dis Clin North Am. 2002;16(3):535-551, vii.
12. Marshall MM, McCormack MC, Kirk GD. Effect of cigarette smoking on HIV acquisition, progression, and mortality. AIDS Educ Prev. 2009; 21 (Suppl 3):28-39.
13. Inner-city health care. American College of Physicians. Ann Intern Med. 1997;126(6):485-490.
14. Alcabes P, Friedland G. Injection drug use and human immunodeficiency virus infection. Clin Infect Dis. 1995;20(6):1467-1479.
15. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86(5):642-654.
16. Crothers K, Butt AA, Gibert CL, Rodriguez-Barradas MC, Crystal S, Justice AC. Increased COPD among HIV-positive compared to HIVnegative veterans. Chest. 2006;130(5):1326-1333.
17. Beck JM, Rosen MJ, Peavy HH. Pulmonary complications of HIV infection. Report of the Fourth NHLBI Workshop. Am J Respir Crit Care Med. 2001;164(11):2120-2126.
18. Diaz PT, King MA, Pacht ER, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med. 2000;132(5):369-372.
19. Sherman CB, Hudson LD, Pierson DJ. Severe precocious emphysema in intravenous methylphenidate (Ritalin) abusers. Chest. 1987;92(6): 1085-1087.
20. Overland ES, Nolan AJ, Hopewell PC. Alteration of pulmonary function in intravenous drug abusers. Prevalence, severity, and characterization of gas exchange abnormalities. Am J Med. 1980;68(2):231-237.
21. Byrd RS, Joad JP. Urban asthma. Curr Opin Pulm Med. 2006;12(1): 68-74.
22. Nascimento OA, Camelier A, Rosa FW, Menezes AM, Perez-Padilla R, Jardim JR. Chronic obstructive pulmonary disease is underdiagnosed and undertreated in Sao Paulo (Brazil): results of the PLATINO study. Braz J Med Biol Res. 2007;40(7):887-895.
23. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991; 109:75-100.
24. Celentano DD, Galai N, Sethi AK, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15(13):1707-1715.
25. Drummond MB, Kirk GD, Ricketts EP, et al. Cross sectional analysis of respiratory symptoms in an injection drug user cohort: the impact of obstructive lung disease and HIV. BMC Pulm Med. 10:27.
26. Ferris BG. Epidemiology standardization project (American Thoracic Society). Am Rev Respir Dis. 1978;118(6 Pt 2):1-120.
27. Fletcher CM. The clinical diagnosis of pulmonary emphysema; an experimental study. Proc R Soc Med. 1952;45(9):577-584.
28. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581-586.
29. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999;159(1):179-187.
30. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319-338.
31. Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup Environ Med. 1998;55(4):272-277.
32. Barros AJ, Hirakata VN. Alternatives for logistic regression in crosssectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol. 2003;3:21.
33. Schiaffino A, Rodriguez M, Pasarin MI, Regidor E, Borrell C, Fernandez E. Odds ratio or prevalence ratio? Their use in cross-sectional studies [in Spanish]. Gac Sanit. 2003;17(1):70-74.
34. Behrens T, Taeger D, Wellmann J, Keil U. Different methods to calculate effect estimates in cross-sectional studies. A comparison between prevalence odds ratio and prevalence ratio. Methods Inf Med. 2004; 43(5):505-509.
35. Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159(7):702-706.
36. Miravitlles M, Soriano JB, Garcia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64(10):863-868.
37. Juday TR, Wu A, Celentano DD, Frick KD, Wang MC, Vlahov D. The role of Medicaid HMO enrollment in the longitudinal utilization of medical care services in a cohort of injecting drug users in Baltimore, Maryland. Subst Abus. 2003;24(1):27-41.
38. Fiscella K, Franks P, Gold MR, Clancy CM. Inequality in quality: addressing socioeconomic, racial, and ethnic disparities in health care. JAMA. 2000;283(19):2579-2584.
39. Van der Molen T, Schokker S. Primary prevention of chronic obstructive pulmonary disease in primary care. Proc Am Thorac Soc. 2009;6(8): 704-706.
40. Vogeli C, Shields AE, Lee TA, et al. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J Gen Intern Med. 2007;22 Suppl 3: 391-395.
41. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2000;160(11):1683-1689.
42. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax. 2008;63(9):768-774.
43. Mannino DM, Doherty DE, Sonia Buist A. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med. 2006;100(1):115-122.
44. Hser YI, McCarthy WJ, Anglin MD. Tobacco use as a distal predictor of mortality among long-term narcotics addicts. Prev Med. 1994;23(1): 61-69.
45. Hurt RD, Offord KP, Croghan IT, et al. Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. JAMA. 1996;275(14):1097-1103.
46. Bednarek M, Gorecka D, Wielgomas J, et al. Smokers with airway obstruction are more likely to quit smoking. Thorax. 2006;61(10): 869-873.
47. Parkes G, Greenhalgh T, Griffin M, Dent R. Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ. 2008;336(7644):598-600.